Gemma Sancho-Pardo

Dr. Gemma Sancho-Pardo


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in European Urology
Verified
Journal Article
Closed access
TLThomas B.L. Lam
Thomas B.L. Lam
SMSteven MacLennan
Steven MacLennan
PWPeter-Paul M. Willemse
Peter-Paul M. Willemse
MMMalcolm D. Mason
Malcolm D. Mason
KPKarin Plass
Karin Plass
NMNicolas Mottet
Nicolas Mottet

1 August 2013 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MFMontserrat Ferrer
Montserrat Ferrer
FGFerran Guedea
Ferran Guedea
JSJosé Francisco Suárez
José Francisco Suárez
BPBelén de Paula
Belén de Paula
VMVíctor Macías
Víctor Macías
FAFerran Aguiló
Ferran Aguiló

1 December 2020 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
GMGustavo Nader Marta
Gustavo Nader Marta
CCCharlotte Coles
Charlotte Coles
OKOrit Kaidar-Person
Orit Kaidar-Person
IMIcro Meattini
Icro Meattini
THTarek Hijal
Tarek Hijal
PPPhilip Poortmans
Philip Poortmans

1 March 2021 in Prostate International
Verified
Journal Article
Open access
FSFrancesco Sanguedolce
Francesco Sanguedolce
GSGemma Sancho-Pardo
Gemma Sancho-Pardo
ASAsier Mercadé Sanchez
Asier Mercadé Sanchez
JLJosep Balaña Lucena
Josep Balaña Lucena
FPFrancesca Pisano
Francesca Pisano
JRJoan Palou Redorta
Joan Palou Redorta
Late onset of radiation-induced haemorrhagic cystitis (RHC) after radiation therapy (RT) for prostate cancer (PCa) may present or evolve severely, requiring hospitalization with invasive interventions. In the present study, we have analysed the prevalence and risk factors associated with the onset of RHC. From January 2002 to May 2017, 1421 patients undertook RT for PCa as a primary, adjuvant, or salvage treatment option. RHC presented in 5.6% (n = 80) of the patients; the diagnosis was based on clinical and endoscopic characteristics. Variables in observation included patients, tumours, and RT-dosimetry characteristics. Patients with a previous history of bladder cancer were excluded. Univariate (Student t/Chi square) and uni-/multivariate Cox regression analysis were performed; the events and time-points were hospitalization and time-to-event, respectively. There were 80 patients with a mean age at RT of 70.1 years (SD 6.4), mean time lag to RHC of 43.9 months (SD 37.5). Median Emergency attendance was two and three times for patients without/with hospitalization, respectively. There were in total 64 admissions with invasive treatment required in 26/36 (72.2%) of the patients hospitalised, including transurethral fulguration in 22 and radical cystectomy in 5. Patients at higher risk of hospitalization were those undertaking antiplatelet/anticoagulant treatment (HR:3.30; CI 95%:1.53–3.30; p = 0.002) and those treated with salvage RT with higher bladder volume receiving >70 Gy (bladder V70) (HR:1.03; CI 95%:1.01–1.05; p = 0.027). At receiving operating characteristic analysis, the cutoff for bladder V70 was 29%. Nearly half of patients presenting RHC may require invasive treatment including cystectomy. Risk factors associated with hospitalization are patients undertaking antiplatelet/coagulant treatment and bladder V70 > 29% in salvage RT patients.

1 December 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
IHIvan Henriquez
Ivan Henriquez
CSCarmen González-San Segundo
Carmen González-San Segundo
JVJesús Olivera Vegas
Jesús Olivera Vegas
CMCristina Gutiérrez Miguélez
Cristina Gutiérrez Miguélez
AHAsunción Hervás-Morón
Asunción Hervás-Morón
PÁPedro Cuesta Álvaro
Pedro Cuesta Álvaro

24 December 2015 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
DJDiana Hernandez Jover
Diana Hernandez Jover
DSD. Salas
D. Salas
DGD. Giménez
D. Giménez
PBP. Buitrago
P. Buitrago
SES. Esquena
S. Esquena
GSGemma Sancho-Pardo
Gemma Sancho-Pardo
Little is known about the clinical impact of using multiparametric MRI to plan early salvage radiotherapy after radical prostatectomy. We aimed to evaluate the incidence and location of recurrence based on pelvic multiparametric MRI findings and to identify clinical variables predictive of positive imaging results. We defined radiological criteria of local and lymph node malignancy and reviewed records and MRI studies of 70 patients with PSA recurrence after radical prostatectomy. We performed univariate and multivariate analysis to identify any association between clinical, pathological and treatment-related variables and imaging results. Multiparametric MRI was positive in 33/70 patients. We found local and lymph node recurrence in 27 patients and 7 patients, respectively, with a median PSA value of 0.38 ng/ml. We found no statistically significant differences between patients with positive and negative multiparametric MRI for any variable. Shorter PSADT was associated with positive lymph nodes (median PSADT: 5.12 vs 12.70 months; p: 0.017). Nearly half the patients had visible disease in multiparametric MRI despite low PSA. Positive lymph nodes incidence should be considered when planning salvage radiotherapy, particularly in patients with a short PSADT.